ArticleTropical medicine and health2026
From Ebola response to adaptable preparedness beyond a single virus.
Article in Tropical medicine and health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Democratic Republic of the Congo (DRC) has been an important setting for Ebola innovation, including ring vaccination with recombinant vesicular stomatitis virus-based Ebola vaccine and the integration of clinical research into emergency response. These advances strengthened preparedness for Zaire ebolavirus (EBOV), but the 2026 Bundibugyo virus disease (BVD) outbreak highlights a remaining limitation: many preparedness capabilities remain closely linked to individual pathogens. Unlike EBOV, Bundibugyo virus (BDBV) has no licensed vaccine specifically indicated for prevention, and current evidence is insufficient to establish clinically meaningful protection from Ervebo against BVD in humans. Operational constraints documented in the current response, including a temporary Ervebo stock-out, limited mobility for vaccination teams, absent vaccination microplans, shortages of personal protective equipment, and gaps in triage and isolation capacity in the Bas-Uélé province, further illustrate that biomedical tools alone cannot ensure effective outbreak control. We propose extending pathogen-specific preparedness through adaptable, platform-based outbreak infrastructure encompassing four linked domains: scientific readiness, research and regulatory readiness, operational readiness, and community readiness. Such platforms should enable rapid evidence generation while retaining pathogen-specific diagnostics, clinical management, vaccines, and epidemiological knowledge. Global preparedness should therefore support transition from uncertainty to evidence and equitable action before transmission outpaces response capacity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.